|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
��ɫ���� |
|
MAPK |
|
�źŴ��� |
| ��������������� | |
|
������ |
|
�ｨ�� |
| PubMed | |
|
Article by HAN Yong-zhi |
|
Article by SUN Jian-fang |
��������MAPK�ź�;��
������, �ｨ��
�й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о��� �Ͼ� 210042
˿��ԭ�����ø·����һ��ϸ�����źŵ���øת��;��,�����˺�������������Ϯ��ת�Ƶȹ���,����˿��ԭ�����ø/ϸ�����źŵ��ڼ�ø·����������Ĺ�ϵ��Ϊ���С�Ŀǰ��Ϊ,���ź�ת��·���е�RAS��ERK,������BRAF��ø�ں������ķ�����չ�п�������Ҫ���á���MAPK/ERK·��Ϊ�ص�,��Ҫ������BRAF��RAS��ERK�ȼ�ø������������Ĺ�ϵ��
Melanoma and MAPK Signal Transduction Pathway
Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China
Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China
Mitogen-activated protein kinase pathway(MAPK) is an extracellular signal protein kinase transduction pathway, extensively involved in the growth, invasion and metastasis of malignant melanoma (MM). In the MAPK superfamily,the MAPK/ERK pathway is considered the most significant. It is recognized now that RAS, ERK, especially BRAF kinase in the MAPK/ERK pathway probably play important roles in the development of MM. Stressing the MAPK/ERK pathway, the article mainly reviews the current understanding of the roles of BRAF, RAS and ERK kinases in MM.
[2] Choi KC,Auersperg N,Leung PC.Mitogen-activated protein kinases in normal and (pre)neoplastic ovarian surface epithelium.Reprod Biol Endocrinol,2003,1:71.
[3] Davies H,Bignell GR,Cox C,et al.Mutations of the BRAF gene in human cancer.Nature,2002,417:949-954.
[4] Wellbrock C,Ogilvie L,Hedley D,et al.V599EB-RAF is an oncogene in melanocytes.Cancer Res,2004,64:2338-2342.
[5] Sumimoto H,Miyagishi M,Miyoshi H,et al.Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference.Oncogene,2004,23:6031-6039.
[6] Goodall J,Wellbrock C,Dexter TJ,et al.The Brn-2 transcription factor links activated BRAF to melanoma proliferation.Mol Cell Biol,2004,24:2923-2931.
[7] Bhatt KV,Spofford LS,Aram G,et al.Adhesion control of cyclin D1 and p27Kipl levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling.Oncogene,2005,24:3459-3471.
[8] Tsavachidou D,Coleman ML,Athanasiadis G,et al.SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.Cancer Res,2004,64:5556-5559.
[9] Yazdi AS,Palmedo G,Flaig MJ,et al.Mutations of the BRAF gene in benign and malignant melanocytic lesions.J Invest Dermatol,2003,121:1160-1162.
[10] Loewe R,Kittler H,Fischer G,et al.BRAF kinase gene V599E mutation in growing melanocytic lesions.J Invest Dermatol,2004,123:733-736.
[11] Dong J,Phelps RG,Qiao R,et al.BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma.Cancer Res,2003,63:3883-3885.
[12] Garraway LA,Widlund HR,Rubin MA,et al.Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.Nature,2005,436:117-122.
[13] Patton EE,Widlund HR,Kutok JL,et al.BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma.Curr Biol,2005,15:249-254.
[14] Maldonado JL,Fridlyand J,Patel H,et al.Determinants of BRAF mutations in primary melanomas.J Natl Cancer Inst,2003,95:1878-1890.
[15] Sasaki Y,Niu C,Makino R,et al.BRAF point mutations in primary melanoma show different prevalences by subtype.J Invest Dermatol,2004,123:177-183.
[16] Chang DZ,Panageas KS,Osman I,et al.Clinical significance of BRAF mutations in metastatic melanoma.J Transl Med,2004,2:46.
[17] Shinozaki M,Fujimoto A,Morton DL,et al.Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas.Clin Cancer Res,2004,10:1753-1757.
[18] Houben R,Becker JC,Kappel A,et al.Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis.J Carcinog,2004,26,3:6.
[19] Kumar R,Angelini S,Czene K,et al.BRAF mutations in metastatic melanoma:a possible association with clinical outcome.Clin Cancer Res,2003,9:3362-3368.
[20] Sharma A,Trivedi NR,Zimmerman MA,et al.Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.Cancer Res,2005,65:2412-2421.
[21] Huntington JT,Shields JM,Der CJ,et al.Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells:role of BRAF mutation and fibroblast growth factor signaling.J Biol Chem,2004,279:33168-33176.
[22] Meyer P,Klaes R,Schmitt C,et al.Exclusion of BRAFV599E as a melanoma susceptibility mutation.Int J Cancer,2003,106:78.
[23] Reifenberger J,Knobbe CB,Sterzinger AA,et al.Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.Int J Cancer,2004,109:377-384.
[24] Cruz F 3rd,Rubin BP,Wilson D,et al.Absence of BRAF and NRAS mutations in uveal melanoma.Cancer Res,2003,63:5761.
[25] Adjei AA.Blocking oncogenic Ras signaling for cancer therapy.J Natl Cancer Inst,2001,93:1062-1074.
[26] Eskandarpour M,Kiaii S,Zhu C,et al.Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells.Int J Cancer.,2005,115:65-73.
[27] Smalley KS.A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer,2003,104:527-532.
[28] Zuidervaart W,van Nieuwpoort F,Stark M,et al.Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS.Br J Cancer,2005,92:2032-2038.